Evidence map›Paper›PMID 34807755›Full record

ArticleAntimicrobial agents and chemotherapy2022

A Photoactivable Natural Product with Broad Antiviral Activity against Enveloped Viruses, Including Highly Pathogenic Coronaviruses.

Thomas Meunier, Lowiese Desmarets, Simon Bordage, Moussa Bamba, Kévin Hervouet, Yves Rouillé, Nathan François, Marion Decossas, Valentin Sencio, François Trottein and 6 more

Open access · hybridAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
5.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Membrane-Targeting Antivirals.International journal of molecular sciences · 2025
    Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Discovery of Anti-Coronavirus Cinnamoyl Triterpenoids Isolated fromInternational journal of molecular sciences · 2023
    Article
  14. Article
  15. Article
  16. Article
  17. New Phenolic Lipids from the Leaves ofMolecules (Basel, Switzerland) · 2023
    Article
  18. Marine drugs · 2023
    Article
  19. Luteolin Isolated fromMolecules (Basel, Switzerland) · 2023
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 2 countries.

Thomas Meunier *University of Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019-UMR 9017-CIIL-Center for Infection and Immunity of Lille, Lille, France.
Lowiese Desmarets *University of Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019-UMR 9017-CIIL-Center for Infection and Immunity of Lille, Lille, France.
Simon Bordage *University of Lille, Université de Liège, Université de Picardie Jules Verne, JUNIA, UMRT 1158 BioEcoAgro, Métabolites Spécialisés d'Origine Végétale, Lille, France.
Moussa BambaUniversity of Lille, Université de Liège, Université de Picardie Jules Verne, JUNIA, UMRT 1158 BioEcoAgro, Métabolites Spécialisés d'Origine Végétale, Lille, France.
Kévin HervouetUniversity of Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019-UMR 9017-CIIL-Center for Infection and Immunity of Lille, Lille, France.
Yves RouilléUniversity of Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019-UMR 9017-CIIL-Center for Infection and Immunity of Lille, Lille, France.ORCID 0000-0003-0788-9271
Nathan FrançoisUniversity of Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019-UMR 9017-CIIL-Center for Infection and Immunity of Lille, Lille, France.
Marion DecossasUniversity of Bordeaux, CBMN UMR 5248, Pessac, France.
Valentin SencioUniversity of Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019-UMR 9017-CIIL-Center for Infection and Immunity of Lille, Lille, France.
François TrotteinUniversity of Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019-UMR 9017-CIIL-Center for Infection and Immunity of Lille, Lille, France.ORCID 0000-0003-3373-1814
Fézan Honora Tra BiUFR Sciences de la Nature, Université Nangui Abrogoua, Abidjan, Côte d'Ivoire.
Olivier LambertUniversity of Bordeaux, CBMN UMR 5248, Pessac, France.
Jean DubuissonUniversity of Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019-UMR 9017-CIIL-Center for Infection and Immunity of Lille, Lille, France.ORCID 0000-0003-1626-7693
Sandrine BelouzardUniversity of Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019-UMR 9017-CIIL-Center for Infection and Immunity of Lille, Lille, France.
Sevser Sahpaz *University of Lille, Université de Liège, Université de Picardie Jules Verne, JUNIA, UMRT 1158 BioEcoAgro, Métabolites Spécialisés d'Origine Végétale, Lille, France.
Karin Séron *University of Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019-UMR 9017-CIIL-Center for Infection and Immunity of Lille, Lille, France.ORCID 0000-0002-9667-133X
Centre National de la Recherche Scientifique · FRUniversité de Bordeaux · FRUniversité de Lille · FRUniversité Nangui Abrogoua · CI

Funding

Agence Nationale de la Recherche (ANR) NanoMERSCNRS and Institut Pasteur of LilleCôte d'Ivoire GovernmentINSERM - Region Hauts de FranceRegion Hauts-de-France I-SITE FlavoCoVUniversity of Lille and CNRS PEPS
6 · The paper itself

Abstract

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak has highlighted the need for broad-spectrum antivirals against coronaviruses (CoVs). Here, pheophorbide a (Pba) was identified as a highly active antiviral molecule against human CoV-229E after bioguided fractionation of plant extracts. The antiviral activity of Pba was subsequently shown for SARS-CoV-2 and Middle East respiratory syndrome coronavirus (MERS-CoV), and its mechanism of action was further assessed, showing that Pba is an inhibitor of coronavirus entry by directly targeting the viral particle. Interestingly, the antiviral activity of Pba depends on light exposure, and Pba was shown to inhibit virus-cell fusion by stiffening the viral membrane, as demonstrated by cryoelectron microscopy. Moreover, Pba was shown to be broadly active against several other enveloped viruses and reduced SARS-CoV-2 and MERS-CoV replication in primary human bronchial epithelial cells. Pba is the first described natural antiviral against SARS-CoV-2 with direct photosensitive virucidal activity that holds potential for COVID-19 therapy or disinfection of SARS-CoV-2-contaminated surfaces.

Indexed as

Biological ProductsCOVID-19Middle East Respiratory Syndrome CoronavirusAntiviral AgentsCryoelectron MicroscopyHumansSARS-CoV-2Antiviral AgentsBiological Productsantiviral agentscoronavirusnatural productvirus entry

Identifiers

PMID34807755
PMCPMC8846325
OpenAlexW3217144227

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.